{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-26-000015","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2026-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.885208+00:00","generated_at":"2026-05-16T02:47:51.600255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B","bullets":["Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).","Full-year 2025 revenue $1.9B (-40% YoY); net loss $(2.8)B ($(7.26) EPS).","2026 guidance: up to 10% revenue growth; R&D ~$3.0B; year-end cash $5.5-6.0B.","U.S. FDA issued Refusal-to-File for seasonal flu vaccine (mRNA-1010); Moderna requested Type A meeting.","Norovirus Phase 3 fully enrolled; intismeran autogene Phase 2 bladder cancer fully enrolled; data readouts expected 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-26-000015","json":"https://secwatch.observer/filing/0001682852-26-000015.json","markdown":"https://secwatch.observer/filing/0001682852-26-000015.md","text":"https://secwatch.observer/filing/0001682852-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/0001682852-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/mrna-20260213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:47:51.600255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}